PDCD1 and cancer: Furthermore, pan-cancer analyses have demonstrated wide variability in response rates to anti-PD-1/PD-L1 therapies—even within the same tumor type—suggesting that existing tissue-based indicators do not fully capture systemic immune escape mechanisms (9).